Eisai 

$8.31
71
+$0.13+1.59%Friday 20:59

Statistics

Day High
8.28
Day Low
8.25
52W High
8.58
52W Low
5.69
Volume
500
Avg. Volume
56,628
Mkt Cap
2.42B
P/E Ratio
31.57
Dividend Yield
3.01%
Dividend
0.25

Upcoming

Dividends

3.01%Dividend Yield
Dec 2026
$0.13
Jun 2026
$0.13
Dec 2025
$0.13
Jun 2025
$0.14
Dec 2024
$0.13
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
21.3%
1Y Growth
-5.47%

Earnings

Feb 10Expected
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Next
-0.07
0.11
0.29
0.47
Expected EPS
0.44595246538
Actual EPS
N/A

Financials

4.74%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
5.43BRevenue
257.22MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ESAIY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Eisai Co., Ltd. is a Japanese pharmaceutical firm that develops, manufactures, and markets a broad spectrum of medical and healthcare products. Its significant therapeutic contributions include Aricept, prescribed for individuals with Alzheimer's disease and dementia with Lewy bodies; Methycobal, targeting peripheral neuropathy; and Fycompa, an antiepileptic medication used as an adjunctive treatment for partial-onset and primary generalized tonic-clonic seizures. The company's product line further encompasses Lyrica for pain management, and Dayvigo, an anti-insomnia agent formulated for adults. In the field of oncology, Eisai offers Lenvima, a molecularly targeted anticancer drug utilized for thyroid cancer, renal cell carcinoma (when administered alongside everolimus), and hepatocellular carcinoma. Another key cancer treatment is Halaven, an anticancer agent functioning as a microtubule dynamics inhibitor, indicated for breast cancer and liposarcoma. Additionally, Eisai provides Pariet, a proton-pump inhibitor effective in managing gastric and duodenal ulcers, reflux esophagitis, and the eradication of Helicobacter pylori infections. It also distributes Humira, a fully human anti-TNF-alpha monoclonal antibody employed in the treatment of autoimmune disorders such as rheumatoid arthritis. For consumer wellness, its offerings include Chocola BB plus, a vitamin B2 supplement beneficial for rough skin and stomatitis, along with a diverse collection of other items, such as third-class over-the-counter (OTC) drugs, designated quasi-drugs, and health-promoting foods. Originally established in 1941 under the name Nihon Eisai Co., Ltd., the company adopted its current name, Eisai Co., Ltd., in 1955 and operates from its headquarters in Tokyo, Japan.
Show More
CEO
Haruo Naito
Employees
10543
Country
Japan
ISIN
US28258A1079
WKN
000A3D5BP

Listings

0 Comments

Share your thoughts

FAQs

What is Eisai stock price today?▼
The current price of ESAIY is $8.31 USD — it has increased by +1.59% in the past 24 hours. Watch Eisai stock price performance more closely on the chart.
What is Eisai stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Eisai stocks are traded under the ticker ESAIY.
Is Eisai stock price growing?▼
ESAIY stock has risen by +2.59% compared to the previous week, the month change is a +2.97% rise, over the last year Eisai has showed a +11.14% increase.
What is Eisai market cap?▼
Today Eisai has the market capitalization of 2.42B
When is the next Eisai earnings date?▼
Eisai is going to release the next earnings report on February 10, 2027.
What were Eisai earnings last quarter?▼
ESAIY earnings for the last quarter are 0.26 USD per share, whereas the estimation was 0.37 USD resulting in a -28.69% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Eisai revenue for the last year?▼
Eisai revenue for the last year amounts to 5.43B USD.
What is Eisai net income for the last year?▼
ESAIY net income for the last year is 257.22M USD.
Does Eisai pay dividends?▼
Yes, ESAIY dividends are paid semi-annual. The last dividend per share was 0.13 . As of today, Dividend Yield (FWD)% is 3.01%.
How many employees does Eisai have?▼
As of November 22, 2026, the company has 10,543 employees.
In which sector is Eisai located?▼
Eisai operates in the Health & Wellness sector.
When did Eisai complete a stock split?▼
Eisai has not had any recent stock splits.
Where is Eisai headquartered?▼
Eisai is headquartered in Tokyo, Japan.